Overview

Location [1]
13q12.3
Pathway
Receptor tyrosine kinase/growth factor signaling
Protein [2]
Vascular endothelial growth factor receptor 1
Synonyms [1]
FLT-1, VEGFR-1, VEGFR1, FLT

Fms-related tyrosine kinase 1 (FLT1) is a gene that encodes a protein that is a receptor tyrosine kinase in the vascular endothelial growth factor receptor (VEGF) family. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.

FLT1 is altered in 3.23% of all cancers with non-small cell lung carcinoma, colorectal adenocarcinoma, melanoma, breast carcinoma, and uterine corpus neoplasm having the greatest prevalence of alterations [3].

FLT1 GENIE Cases - Top Diseases

The most common alterations in FLT1 are FLT1 Mutation (2.78%), FLT1 Missense (2.56%), FLT1 Amplification (0.39%), FLT1 Nonsense (0.16%), and FLT1 Frameshift (0.11%) [3].

FLT1 GENIE Cases - Top Alterations

Significance of FLT1 in Diseases

Malignant Solid Tumor +

Non-Small Cell Lung Carcinoma +

Multiple Myeloma +

Nasal Cavity And Paranasal Sinus Carcinoma +

Urothelial Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Nasopharyngeal Carcinoma +

Esophageal Carcinoma +

Gastric Carcinoma +

B-Cell Non-Hodgkin Lymphoma +

Lymphoma +

Non-Hodgkin Lymphoma +

Pancreatic Carcinoma +

Gastrointestinal Stromal Tumor +

Cancer +

Hepatobiliary Neoplasm +

Lip And Oral Cavity Carcinoma +

Malignant Laryngeal Neoplasm +

Malignant Salivary Gland Neoplasm +

Oropharyngeal Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.